Paradigm4’s Marilyn Matz and Zachary Pitluk discuss the challenges of integrating data from heterogeneous sources and how the company’s plaform and apps combine the cutting edge of computer science and a sensibility geared toward the unique needs of pharma and biopharma to provide end-to-end solutions.
The past few years have seen several flashy demonstrations of how artificial intelligence (AI) algorithms may transform biomedical research, particularly with respect to drug discovery.
Over the past 5 decades or so, the growing understanding that RNA can influence protein function through routes other than direct translation has opened the prospect of discovering small molecules for tackling diseases in novel ways.
Metabolomics—often referred to as the youngest of the omics—provides key insight into phenotype. However, bulk metabolomics requires the homogenization of the sample and is thus unable to discern metabolic differences at a cellular level.
